Key facts
- This page summarizes BVF PARTNERS L P/IL's Form 3 filing for enGene Holdings Inc. (ENGN).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 Nov 2023, 16:48.
BVF PARTNERS L P/IL - 31 Oct 2023 Form 3 Insider Report for enGene Holdings Inc. (ENGN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ENGN
- Reported as of
- 31 Oct 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 13 Nov 2023, 16:48:23 UTC
- Prior SEC filing
- 14 Sep 2023
- Next SEC filing
- 06 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BVF PARTNERS L P/IL filed Form 3 for enGene Holdings Inc. (ENGN) on 13 Nov 2023.
Change
- Previous filing in this sequence was filed on 14 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENGN
holding
Class A Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,204,412
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
ENGN
holding
Class A Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 912,776
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F3
ENGN
holding
Class A Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 104,257
- Date
- 31 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENGN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Oct 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 505,835
- Exercise price
- $11.50
- Footnotes
- F1, F2, F5
ENGN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Oct 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 383,352
- Exercise price
- $11.50
- Footnotes
- F1, F3, F5
ENGN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Oct 2023
- Ownership
- Direct
- Underlying class
- Class A Common Shares
- Underlying amount
- 43,786
- Exercise price
- $11.50
- Footnotes
- F1, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 that collectively beneficially owns over 10% of the Issuer's outstanding Class A Common Shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Footnote F2
Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Footnote F3
Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Footnote F4
Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Footnote F5
Each warrant entitles the holder thereof to purchase one Class A Common Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the combination between the Issuer and Forbion European Acquisition Corp., which occurred on October 31, 2023, subject to certain conditions.